Claims for Patent: 9,439,900

Summary for Patent: 9,439,900

Title:	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Abstract:	There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
Inventor(s):	Fischer; Andreas (Uppsala, SE)
Assignee:	Orexo AB (Uppsala, SE)
Application Number:	14/577,823
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,439,900
Patent Claims:	1. A pharmaceutical composition in the form of a tablet suitable for sublingual administration comprising: buprenorphine, or a pharmaceutically acceptable salt thereof, provided in the form of microparticles, a weak acid, provided in the form of particles, which particles are separate from the microparticles of buprenorphine, or a pharmaceutically acceptable salt thereof, a disintegrant, and naloxone or a pharmaceutically acceptable salt thereof, wherein the per tablet dosage of buprenorphine (calculated as the free base) is 11.4 mg, 8.6 mg, 5.7 mg, 2.9 mg, or 1.4 mg; and wherein the per tablet dosage ratio of buprenorphine:naloxone dose (calculated as free bases) is about 4:1. 2. The composition as claimed in claim 1 wherein the disintegrant is selected from the group of croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone and mixtures thereof. 3. The composition as claimed in claim 1, wherein the disintegrant is in particulate form, having a weight based mean diameter of between about 0.1 .mu.m and about 100 .mu.m. 4. The composition as claimed in claim 1, wherein the naloxone or pharmaceutically acceptable salt thereof is provided in the form of particles. 5. The composition as claimed in claim 4, wherein the microparticles of buprenorphine or salt thereof and the particles of naloxone or salt thereof each have a weight based mean diameter of between about 0.5 .mu.m and about 15 .mu.m. 6. The composition as claimed in claim 1, wherein the weak acid is selected from the group consisting of citric acid, malic acid, tartaric acid, fumaric acid, adipic acid, succinic acid, lactic acid, acetic acid, oxalic acid, maleic acid, ammonium chloride, and a combination of such acids. 7. The composition as claimed in claim 1 further comprising an alkaline salt of a weak acid, provided in the form of particles. 8. The composition as claimed in claim 7, wherein the alkaline salt of the weak acid comprises an alkaline salt of citric acid, malic acid, tartaric acid, fumaric acid, adipic acid, succinic acid, lactic acid, acetic acid, oxalic acid, or maleic acid. 9. The composition as claimed in claim 1 further comprising water-soluble carrier particles. 10. The composition as claimed in claim 9, wherein the water-soluble carrier particles are of a size, based on a weight based mean diameter, of about 100 .mu.m to about 800 .mu.m. 11. The composition as claimed in claim 9, wherein the water-soluble carrier particles comprise a sugar or sugar alcohol. 12. The composition as claimed in claim 9, wherein the water-soluble carrier particles comprise mannitol. 13. The composition as claimed in claim 9, wherein the microparticles of buprenorphine are presented upon the surfaces of the water-soluble carrier particles. 14. The composition as claimed in claim 9, wherein the particles of the weak acid are presented upon the surfaces of, and/or between, the water-soluble carrier particles. 15. The composition as claimed in claim 1, wherein the tablet has a crushing strength in the range of about 10N to about 100N. 16. The composition as claimed in claim 1, wherein the microparticles of buprenorphine or salt thereof are in associative admixture with the particles of weak acid. 17. The composition as claimed in claim 1, wherein the microparticles of buprenorphine or salt thereof are in contact with the particles of weak acid. 18. The composition as claimed in claim 1, wherein the weak acid is citric acid, the disintegrant is croscarmellose sodium, and the composition further comprises mannitol, sodium citrate and microcrystalline cellulose.